- Conditions
- Primary Membranous Nephropathy
- Interventions
- SNP-ACTH (1-39) Gel, Rituximab
- Drug
- Lead sponsor
- Cerium Pharmaceuticals, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 148 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2027
- U.S. locations
- 19
- States / cities
- Los Angeles, California • San Dimas, California • Tarzana, California + 15 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Showing 481–504
of 8,003
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Neoplasms
- Interventions
- Dostarlimab
- Biological
- Lead sponsor
- Tesaro, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 729 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2028
- U.S. locations
- 48
- States / cities
- Birmingham, Alabama • Goodyear, Arizona • Scottsdale, Arizona + 38 more
- Conditions
- Cancer, Mortality, Chronic Diseases
- Interventions
- Not listed
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 50 Years to 71 Years
- Enrollment
- 566,398 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2050
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Colorectal Cancer
- Interventions
- Atezolizumab, Bevacizumab, Cobimetinib
- Drug
- Lead sponsor
- Hoffmann-La Roche
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 51 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2019
- U.S. locations
- 4
- States / cities
- Aurora, Colorado • New York, New York • Nashville, Tennessee + 1 more
- Conditions
- Multiple Myeloma
- Interventions
- Atezolizumab (MPDL3280A), an engineered anti-PD-L1 antibody, Daratumumab, Lenalidomide, Pomalidomide, Dexamethasone
- Drug
- Lead sponsor
- Hoffmann-La Roche
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 85 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2021
- U.S. locations
- 31
- States / cities
- Birmingham, Alabama • Little Rock, Arkansas • La Jolla, California + 24 more
- Conditions
- Brain and Central Nervous System Tumors
- Interventions
- carboplatin, pyrazoloacridine
- Drug
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 60 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2000 – 2007
- U.S. locations
- 22
- States / cities
- Scottsdale, Arizona • Jacksonville, Florida • Peoria, Illinois + 19 more
- Conditions
- Acute Lymphoblastic Leukemia
- Interventions
- Doxorubicin, Cytarabine, Methotrexate, Vincristine, Cyclophosphamide, Methylprednisone, Hydrocortisone Sodium Succinate, Dexamethasone, 6-MP, PEG-Asparaginase, Imatinib, Etoposide, Radiation Therapy, E. coli Asparaginase
- Drug · Procedure
- Lead sponsor
- Dana-Farber Cancer Institute
- Other
- Eligibility
- 18 Years to 50 Years
- Enrollment
- 112 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2020
- U.S. locations
- 7
- States / cities
- Boston, Massachusetts • New York, New York • Columbus, Ohio + 1 more
- Conditions
- Multiple Myeloma, Leukemia, Plasma Cell
- Interventions
- Carfilzomib, Melphalan, Filgrastim
- Drug
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 3 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2014
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Muscular Atrophy, Spinal
- Interventions
- Placebo, Risdiplam
- Drug
- Lead sponsor
- Hoffmann-La Roche
- Industry
- Eligibility
- 2 Years to 25 Years
- Enrollment
- 231 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2023
- U.S. locations
- 2
- States / cities
- Palo Alto, California • New York, New York
- Conditions
- Psoriasis
- Interventions
- teplizumab
- Biological
- Lead sponsor
- MacroGenics
- Industry
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 1 participant
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2010
- U.S. locations
- 2
- States / cities
- Ann Arbor, Michigan • Portland, Oregon
- Conditions
- Healthy Subjects, Pharmacokinetics of ASP2408
- Interventions
- ASP2408, Placebo
- Drug
- Lead sponsor
- Astellas Pharma Global Development, Inc.
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 65 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2011 – 2012
- U.S. locations
- 1
- States / cities
- Baltimore, Maryland
- Conditions
- Immunosuppression For Disease
- Interventions
- BMS-986020, Rosuvastatin
- Drug
- Lead sponsor
- Bristol-Myers Squibb
- Industry
- Eligibility
- 18 Years to 50 Years
- Enrollment
- 26 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2014
- U.S. locations
- 1
- States / cities
- San Antonio, Texas
- Conditions
- Obstructive Sleep Apnea, Healthy Subjects
- Interventions
- Placebo, Lemborexant 10 mg, Lemborexant 25 mg
- Drug
- Lead sponsor
- Eisai Inc.
- Industry
- Eligibility
- 18 Years to 90 Years
- Enrollment
- 146 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2018
- U.S. locations
- 11
- States / cities
- Glendale, Arizona • Phoenix, Arizona • San Diego, California + 7 more
- Conditions
- Acne Vulgaris
- Interventions
- Red Light (PDT)
- Drug
- Lead sponsor
- Dermira, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 12 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2013
- U.S. locations
- 1
- States / cities
- Paramus, New Jersey
- Conditions
- Pancreatic Neoplasms, Ovarian Neoplasms, Breast Neoplasms, Prostatic Neoplasms
- Interventions
- BTP-114
- Drug
- Lead sponsor
- Placon Therapeutics
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 95 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2020
- U.S. locations
- 8
- States / cities
- Sarasota, Florida • Boston, Massachusetts • St Louis, Missouri + 4 more
- Conditions
- B-cell Acute Lymphoblastic Leukemia, B Lineage Lymphoblastic Lymphoma
- Interventions
- Autologous, humanized anti-CD22 CAR T cell therapy (CART22-65s), Autologous, humanized anti-CD19 CAR T cell therapy (huCART19)
- Biological
- Lead sponsor
- Stephan Grupp MD PhD
- Other
- Eligibility
- Up to 29 Years
- Enrollment
- 93 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2029
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania
- Conditions
- Cognitive Change
- Interventions
- C1 - Standard Perceptual Learning (SPL), C2 - Long Training (LT), C3 - Short Staircases (SS), C4 - Mixed Difficulty (MD), C5 - Noise Training (NT), C6 - Training with Flankers (TWF), C7 - Parafoveal Training (PT), C8 - Stimulus Variety (SV), C8a - Complex Features (CF), C9 - Exogenous Attention Training (ExAT), C10 - Endogenous Attention Training (EnAT), C11 - Multisensory Facilitation (MF), No Contact Control
- Behavioral
- Lead sponsor
- University of Wisconsin, Madison
- Other
- Eligibility
- 18 Years to 85 Years
- Enrollment
- 1,140 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2023 – 2027
- U.S. locations
- 3
- States / cities
- Riverside, California • Boston, Massachusetts • Madison, Wisconsin
- Conditions
- Squamous Cell Carcinoma of the Head and Neck
- Interventions
- Nivolumab
- Biological
- Lead sponsor
- Bristol-Myers Squibb
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 509 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2021
- U.S. locations
- 1
- States / cities
- Mount Laurel, New Jersey
- Conditions
- Prostate Cancer
- Interventions
- BNT112, Cemiplimab
- Biological · Drug
- Lead sponsor
- BioNTech SE
- Industry
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 75 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2024
- U.S. locations
- 5
- States / cities
- Tucson, Arizona • Miami, Florida • Pittsburgh, Pennsylvania + 2 more
- Conditions
- Ischemic Stroke
- Interventions
- MultiStem, Placebo
- Biological
- Lead sponsor
- Healios K.K.
- Industry
- Eligibility
- 18 Years to 83 Years
- Enrollment
- 134 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2015
- U.S. locations
- 26
- States / cities
- Los Angeles, California • Stanford, California • Miami, Florida + 20 more
- Conditions
- Healthy Participants
- Interventions
- Elecoglipron Reference Formulation Dose A, Elecoglipron Test formulation 1 Dose A, Elecoglipron Reference Formulation Dose B, Elecoglipron Test formulation 1 Dose B, Elecoglipron Test formulation 2 Dose A, Elecoglipron Test formulation 2 Dose B
- Drug
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 152 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2026
- U.S. locations
- 2
- States / cities
- Glendale, California • Brooklyn, Maryland
- Conditions
- Muscle-Invasive Bladder Carcinoma, Metastatic Urothelial Carcinoma
- Interventions
- SEphB4-HSA, Pembrolizumab, Gemcitabine, Cisplatin, Enfortumab vedotin
- Drug
- Lead sponsor
- Vasgene Therapeutics, Inc
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 700 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2034
- U.S. locations
- 1
- States / cities
- Santa Monica, California
- Conditions
- Healthy Volunteers
- Interventions
- [11C] raclopride, liquid nutritive stimulus, Tasteless Oral Stimulus Solution, Minimally Processed Diet, Ultra Processed Diet, Baseline Diet
- Drug · Other
- Lead sponsor
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
- NIH
- Eligibility
- 18 Years to 45 Years
- Enrollment
- 140 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2030
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Advanced Cancer
- Interventions
- BMS-986406, Nivolumab, Carboplatin, Pemetrexed, Paclitaxel
- Biological · Drug
- Lead sponsor
- Bristol-Myers Squibb
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 77 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2024
- U.S. locations
- 9
- States / cities
- Birmingham, Alabama • La Jolla, California • Los Angeles, California + 5 more